BR112018068075A2 - inibidores de fosfatidilinositol 3-quinase gama - Google Patents

inibidores de fosfatidilinositol 3-quinase gama

Info

Publication number
BR112018068075A2
BR112018068075A2 BR112018068075A BR112018068075A BR112018068075A2 BR 112018068075 A2 BR112018068075 A2 BR 112018068075A2 BR 112018068075 A BR112018068075 A BR 112018068075A BR 112018068075 A BR112018068075 A BR 112018068075A BR 112018068075 A2 BR112018068075 A2 BR 112018068075A2
Authority
BR
Brazil
Prior art keywords
phosphatidylinositol
kinase gamma
gamma inhibitors
compounds
pi3k
Prior art date
Application number
BR112018068075A
Other languages
English (en)
Inventor
Tyrchan Christian
Petersen Jens
Karabelas Konstantinos
Perry Matthew
Mogemark Mickael
Pemberton Nils
Zlatoidsky Pavol
Cox Rhona
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR112018068075A2 publication Critical patent/BR112018068075A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

são divulgados certos novos compostos (incluindo os seus sais farmaceuticamente aceitáveis), que inibem a atividade de fosfatidilinositol 3-quinase gama (pi3k¿), a sua utilidade no tratamento e/ou prevenção de afeções clínicas, incluindo doenças respiratórias, tais como asma e doença pulmonar obstrutiva crônica (copd), para o seu uso em terapia, para composições farmacêuticas contendo os mesmos e para processos para preparar tais compostos.
BR112018068075A 2016-03-10 2017-03-09 inibidores de fosfatidilinositol 3-quinase gama BR112018068075A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662306328P 2016-03-10 2016-03-10
PCT/EP2017/055552 WO2017153527A1 (en) 2016-03-10 2017-03-09 Novel inhibitors of phosphatidylinositol 3-kinase gamma

Publications (1)

Publication Number Publication Date
BR112018068075A2 true BR112018068075A2 (pt) 2019-01-08

Family

ID=58264542

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018068075A BR112018068075A2 (pt) 2016-03-10 2017-03-09 inibidores de fosfatidilinositol 3-quinase gama

Country Status (13)

Country Link
US (2) US10858355B2 (pt)
EP (1) EP3426652B1 (pt)
JP (1) JP6893520B2 (pt)
KR (1) KR20180117693A (pt)
CN (1) CN108779110B (pt)
AR (1) AR107840A1 (pt)
AU (1) AU2017229445B2 (pt)
BR (1) BR112018068075A2 (pt)
CA (1) CA3015893C (pt)
EA (1) EA036388B1 (pt)
MX (1) MX2018010894A (pt)
TW (1) TWI746525B (pt)
WO (1) WO2017153527A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
US11396502B2 (en) 2018-11-13 2022-07-26 Incyte Corporation Substituted heterocyclic derivatives as PI3K inhibitors
US11078204B2 (en) 2018-11-13 2021-08-03 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
US20230227446A9 (en) 2019-04-10 2023-07-20 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphatidylinositol 3-kinase inhibitors
WO2022017371A1 (zh) * 2020-07-21 2022-01-27 中国医药研究开发中心有限公司 具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途
WO2024046454A1 (zh) * 2022-09-01 2024-03-07 上海海雁医药科技有限公司 杂芳基取代的吡啶并吡咯酮衍生物、其药物组合物及应用
WO2024051784A1 (zh) * 2022-09-09 2024-03-14 上海璎黎药业有限公司 一种含氮杂环化合物、其药物组合物及应用
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
CA2598409A1 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
EA200801716A1 (ru) * 2006-01-18 2009-04-28 Амген Инк. Тиазольные соединения и их применение
EP2016075A1 (en) * 2006-05-03 2009-01-21 AstraZeneca AB Thiazole derivatives and their use as anti-tumour agents
EP1894931A1 (en) * 2006-08-30 2008-03-05 Cellzome Ag Triazole derivatives as kinase inhibitors
EP2327704A4 (en) * 2008-08-29 2012-05-09 Shionogi & Co RING-CONDENSED AZOL DERIVATIVE WITH PI3K-INHIBITING EFFECT
EP2398810A1 (en) * 2009-02-17 2011-12-28 Vertex Pharmaceuticals Incorporated Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase
ES2655391T3 (es) * 2009-12-22 2018-02-19 Vertex Pharmaceuticals Incorporated Inhibidores isoindolinona de fosfatidilinositol 3-quinasa
CN104379573A (zh) * 2012-04-20 2015-02-25 艾伯维公司 异吲哚酮衍生物
CN105722838B (zh) * 2013-09-25 2017-10-24 沃泰克斯药物股份有限公司 磷脂酰肌醇3‑激酶‑γ的选择性抑制剂
EA032075B1 (ru) 2014-04-24 2019-04-30 Новартис Аг Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы
ES2761569T3 (es) 2014-04-24 2020-05-20 Novartis Ag Derivados aminopiridínicos como inhibidores de fosfatidilinositol 3-cinasas
JP6404944B2 (ja) 2014-04-24 2018-10-17 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害薬としてのピラジン誘導体

Also Published As

Publication number Publication date
EP3426652B1 (en) 2021-12-01
JP2019507788A (ja) 2019-03-22
EA036388B1 (ru) 2020-11-03
EA201891931A1 (ru) 2019-04-30
KR20180117693A (ko) 2018-10-29
CN108779110B (zh) 2021-10-29
WO2017153527A1 (en) 2017-09-14
AR107840A1 (es) 2018-06-13
EP3426652A1 (en) 2019-01-16
TW201808945A (zh) 2018-03-16
AU2017229445B2 (en) 2019-07-11
MX2018010894A (es) 2018-11-09
US20210047312A1 (en) 2021-02-18
JP6893520B2 (ja) 2021-06-23
US20200299289A1 (en) 2020-09-24
AU2017229445A1 (en) 2018-10-25
US10858355B2 (en) 2020-12-08
CA3015893A1 (en) 2017-09-14
TWI746525B (zh) 2021-11-21
CA3015893C (en) 2021-11-09
CN108779110A (zh) 2018-11-09

Similar Documents

Publication Publication Date Title
BR112018068075A2 (pt) inibidores de fosfatidilinositol 3-quinase gama
CY1123391T1 (el) (2s)-n-[(1s)-1-kyano-2-φainyλaιθyλ]-1,4-oξazeπan-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης ι
BR112016015818A2 (pt) Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1
BR112019004719A2 (pt) derivados de 5-[2-(piridin-2-ilamino)-1,3-tiazol-5-il]-2,3-di-hidro-1h-isoindol-1-ona e seu uso como inibidores duais de fosfatidilinositol 3-quinase delta e gama
BR112015020787A2 (pt) inibidores quinazolínicos de formas mutantes ativantes do receptor do fator de crescimento epidérmico
BR112016015983A2 (pt) Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
BR112017024933A8 (pt) Alvocidib produce com a bioavailabilidade aumentada
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112018068532A2 (pt) combinações de inibidores de lsd1 para o tratamento de malignidades hematológicas
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
BR112016022598A8 (pt) composição aerossol farmacêutica na forma de um pó seco para liberação pulmonar, forma de dosagem unitária, pacote farmacêutico, kit e uso
BR112017006073A2 (pt) derivado de ácido 4-(4-(4-fenilureído-naftalen-1-il)óxi-piridin-2-il)amino-benzoico como inibidor de quinase de p38
BR112015019412A8 (pt) inibidores de bace1, seus usos, e composição farmacêutica
BR112019024322A2 (pt) Compostos e composições terapêuticos e métodos de uso dos mesmos
BR112013026397A2 (pt) Compostos cromenona como inibidores de pi 3-cinase para o tratamento de câncer
AR104068A1 (es) Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
BR112017019653A2 (pt) derivados heteroaril bicíclicos fundidos tendo atividade como inibidores de phd
BR112017021522A2 (pt) ?composto, composição farmacêutica, uso de composto e método de tratamento de distúrbios?
BR112017015474A2 (pt) inibidores de bace1
BR112022013227A2 (pt) Inibidores de btk
BR112017028240A2 (pt) compostos 4-(3-pirazolilamino)-benzimidazol e seu uso como inibidores de jak1
BR112019000603A2 (pt) composto, composição farmacêutica, método para o tratamento de doenças e uso do composto
BR112016003039B8 (pt) Compostos inibidores de calicreína plasmática, composições farmacêuticas compreendendo os mesmos e seus usos
BR112017005050A2 (pt) composição farmacêutica, nebulizador e método de tratamento ou prevenção de doenças
EA202090672A2 (ru) ТИАЗОЛКАРБОКСАМИДЫ И ПИРИДИНКАРБОКСАМИДЫ, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Pim-КИНАЗЫ

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2713 DE 03-01-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.